Feng Kexin, He Xin, Qin Ling, Ma Zihuan, Liu Siyao, Jia Ziqi, Ren Fei, Cao Heng, Wu Jiang, Ma Dongxu, Wang Xiang, Xing Zeyu
Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Beijing ChosenMed Clinical Laboratory Co. Ltd., Jinghai Industrial Park, Economic and Technological Development Area, Beijing, 100176, China.
Heliyon. 2024 Aug 2;10(15):e35553. doi: 10.1016/j.heliyon.2024.e35553. eCollection 2024 Aug 15.
Breast cancer (BC) is a highly common form of cancer that occurs in many parts of the world. However, early -stage BC is curable. Many patients with BC have poor prognostic outcomes owing to ineffective diagnostic and therapeutic tools. The ubiquitination system and associated proteins were found influencing the outcome of individuals with cancer. Therefore, developing a biomarker associated with ubiquitination genes to forecast BC patient outcomes is a feasible strategy.
The primary goal of this work was to develop a novel risk score signature capable of accurately estimate the future outcome of patients with BC by targeting ubiquitinated genes.
Univariate Cox regression analysis was conducted utilizing the E1, E2, and E3 ubiquitination-related genes in the GSE20685 dataset. Genes with p < 0.01 were screened again using the Non-negative Matrix Factorization (NMF) algorithm, and the resulting hub genes were composed of a risk score signature. Patients were categorized into two risk groups, and the predictive effect was tested using Kaplan-Meier (KM) and Receiver Operating Characteristic (ROC) curves. This risk score signature was later validated using multiple external datasets, namely TCGA-BRAC, GSE1456, GSE16446, GSE20711, GSE58812 and GSE96058. Immuno-microenvironmental, single-cell, and microbial analyses were also performed.
The selected gene signature comprising six ubiquitination-related genes (, , , , , and ) showed good prognostic power in patients with BC. It was validated using multiple externally validated datasets, with KM curves showing significant differences in survival (p < 0.05). The KM curves also demonstrated superior predictive ability compared to traditional clinical indicators. Single-cell analysis revealed that Vd2 gd T cells were less abundantin the low-risk group, whereas patients in the high-risk group lacked myeloid dendritic cells. Tumor microbiological analysis revealed a notable variation in microorganism diversity between the high- and low-risk groups.
This study established an risk score signature consisting of six ubiquitination genes, that can accurately forecast the outcome of patients with BC using multiple datasets. It can provide personalized and targeted assistance to provide the evaluation and therapy of individuals having BC.
乳腺癌(BC)是一种在世界许多地区都极为常见的癌症形式。然而,早期乳腺癌是可治愈的。由于诊断和治疗工具的有效性不足,许多乳腺癌患者的预后结果较差。泛素化系统及相关蛋白被发现会影响癌症患者的预后。因此,开发一种与泛素化基因相关的生物标志物以预测乳腺癌患者的预后是一种可行的策略。
本研究的主要目标是通过靶向泛素化基因开发一种能够准确估计乳腺癌患者未来预后的新型风险评分特征。
利用GSE20685数据集中的E1、E2和E3泛素化相关基因进行单变量Cox回归分析。使用非负矩阵分解(NMF)算法再次筛选p < 0.01的基因,得到的核心基因构成一个风险评分特征。将患者分为两个风险组,并使用Kaplan-Meier(KM)曲线和受试者工作特征(ROC)曲线测试预测效果。该风险评分特征随后在多个外部数据集(即TCGA-BRAC、GSE1456、GSE16446、GSE20711、GSE58812和GSE96058)中进行验证。还进行了免疫微环境、单细胞和微生物分析。
所选的包含六个泛素化相关基因(、、、、、和)的基因特征在乳腺癌患者中显示出良好的预后能力。它在多个外部验证数据集中得到验证,KM曲线显示生存存在显著差异(p < 0.05)。与传统临床指标相比,KM曲线还显示出卓越的预测能力。单细胞分析显示,低风险组中Vd2 gd T细胞较少,而高风险组患者缺乏髓样树突状细胞。肿瘤微生物分析显示,高风险组和低风险组之间微生物多样性存在显著差异。
本研究建立了一个由六个泛素化基因组成的风险评分特征,该特征能够使用多个数据集准确预测乳腺癌患者预后。它可为乳腺癌患者的评估和治疗提供个性化和有针对性的帮助。